Tibet Pharmaceuticals to Host First Quarter 2011 Earnings Conference Call on May 17, 2011 at 9:30 am Eastern
SHANGRI-LA COUNTY, China, May 12, 2011 /PRNewswire/ — Tibet Pharmaceuticals, Inc. (NASDAQ: TBET), an emerging specialty pharmaceutical company engaged in the development, manufacturing and marketing of traditional Tibetan medicine in China, will host a conference call on Tuesday, May 17 at 9:30 am Eastern to discuss its financial results for the first quarter ended March 31, 2011. Tibet’s Form 10-Q and corresponding earnings release are expected to be filed on May 16, 2011.
“We look forward to discussing our latest financial performance during our upcoming conference call,” said Taylor Guo, Chief Executive Officer of Tibet Pharmaceuticals. “Tibet has consistently delivered strong revenue and earnings growth, and this was the case again not more than a month ago when we reported our record financial results for the 2010 fiscal year. As we continue to focus on our organic growth while implementing potential future acquisitions, we believe this trend will accelerate in 2011.”
The teleconference can be accessed by dialing 877-407-0778 when calling within the United States or 201-689-8565 when calling internationally. Please dial in 10 minutes prior to the beginning of the call. There will be a playback available until May 31, 2011. To listen to the playback dial 877-660-6853 when calling within the United States, or 201-612-7415 when calling internationally and use account number: 286, in conjunction with replay ID number: 372828.
The conference call will be simultaneously webcast and available on the company’s website, www.tibetpharmaceuticals.com, under the “Events and Presentations” tab of the “Investors” section.
About Tibet Pharmaceuticals, Inc.
Based in Shangri-La County, Yunnan Province, China, Tibet Pharmaceuticals, Inc. (NASDAQ: TBET) is a rapidly growing specialty pharmaceutical company engaged in the research, development, manufacturing and marketing of modernized traditional Tibetan medicines in China. With over 190 employees and nation-wide distributors, the company develops both prescription and over-the-counter traditional Tibetan medicines that promote health in human respiratory, digestive, urinary and reproductive systems. Tibet Pharmaceuticals’ products are sold throughout China, with a majority of sales concentrated in the southern provinces, most notably Yunnan Province, where the company’s 52,000 sq. ft. GMP-certified manufacturing facilities are located. The access to key raw materials, not generally available outside the province, provides a significant advantage for Tibet Pharmaceuticals.
For comprehensive investor relations material, including fact sheets, research reports, presentations and video, please follow the appropriate link: Research Report, Investor Portal and Overview Video.
For more information on Tibet Pharmaceuticals, please visit:
This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. Specifically, references herein to contemplated growth in company revenues and/or earnings are forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks contained in reports filed by the company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.
Financial Communications Contact:
Trilogy Capital Partners – Asia
Darren Minton, President
SOURCE Tibet Pharmaceuticals, Inc.